Drug Discovery Today
AUGUST 20, 2021
• ELRIG Drug Discovery 2021, ACC Liverpool, UK, 19–20 October• Face-to-face event aims to re-connect, re-invent, and re-imagine drug discovery• SLAS’s Innovation AveNEW promotes start-ups by awarding free-of-charge exhibition space and access to a network of potential business partners
Drug Patent Watch
AUGUST 16, 2021
I’ll be leading a workshop on generic portfolio management, and also giving a talk, at the 14th annual Marcus Evans event on Portfolio Planning and Partnerships for Generics. The event…. The post Upcoming workshop on generic portfolio management appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
AUGUST 17, 2021
The generic prescription market is being disrupted—but not by the big, bad spaceman from Seattle. Instead, consider how GoodRx is affecting patients, payers, and PBMs. Below I summarize the latest financial results for GoodRx’s discount card business. We estimate that the company accounted for $4.1 billion in U.S. prescription revenues for 2021. That’s about six times its 2016 figure.
The Pharma Data
AUGUST 19, 2021
The INHANCE™ Shoulder System empowers surgeons to treat a broad range of cases with a streamlined, comprehensive implant offering that features common instrumentation and unique interoperative flexibility. Designed for hospitals as well as outpatient and ASC settings where economic value and operational efficiency are critical considerations. Today, The Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson,** introduces
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Discovery Today
AUGUST 18, 2021
A new study, produced in partnership between the Royal Veterinary College (RVC), the Wellcome Sanger Institute, Imperial College and the Vector Borne and Neglected Tropical Disease Control Division of the Ministry of Health, Uganda, has been published in Nature Communications. This research paves the way for a more effective genomic surveillance of schistosomiasis, a major human parasite.
Drug Patent Watch
AUGUST 14, 2021
Annual Drug Patent Expirations for GLYXAMBI Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Boehringer Ingelheim drug GLYXAMBI appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
The Pharma Data
AUGUST 19, 2021
We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine. In July , Johnson & Johnson shared data demonstrating that our single-shot COVID-19 vaccine generated strong, persistent immune activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.
Drug Discovery Today
AUGUST 18, 2021
Wallops Flight Facility, VA. August 10, 2021 - An 18-year-old high school graduate has developed an elegant new way to gauge the liver health of astronauts—and it could someday help solve an enduring medical mystery in space.
Drug Patent Watch
AUGUST 20, 2021
This chart shows the pharmaceutical companies with the most patents in Finland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
Molecule Blog
AUGUST 19, 2021
TL;DR: This week, the first university biomedical intellectual property (IP) and research project was funded as an NFT (non-fungible token), enabled by a pioneering innovation at Molecule. The IP-NFT enables new fundraising and collaboration strategies for researchers by combining legal and technical frameworks with NFT technology. Early-stage research can be financed without endless grant applications, creating a startup and raising VC or needing to file a patent.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The Pharma Data
AUGUST 19, 2021
Oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2021 World Conference on Lung Cancer (WCLC) shows evidence that the bispecific mechanism of action for RYBREVANT TM can provide anti-tumor activity against either EGFR-mutated or MET-mutated non-small cell lung cancer. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment
Drug Discovery Today
AUGUST 16, 2021
Manchester, UK, August 11, 2021: Monument Therapeutics, a stratified medicine company, today announced Monument Therapeutics the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments.
Drug Patent Watch
AUGUST 19, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Spain? appeared first on DrugPatentWatch - Make Better Decisions.
Crown Bioscience
AUGUST 16, 2021
While the authentication of biosamples (i.e., cell lines, organoids, xenograft and homograft models) has long been recommended, misidentification and contamination remains a problem. In this post, we explore two of the traditional (low throughput) genomic-based assays used for assessing biosample authentication and contamination: short tandem repeat (STR) and single nucleotide polymorphism (SNP) analysis.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
The Pharma Data
AUGUST 19, 2021
Johnson & Johnson (NYSE: JNJ) today announced that Mr. Alex Gorsky, currently Chairman and Chief Executive Officer, will serve as Executive Chairman of Johnson & Johnson and transition the Chief Executive Officer role to Mr. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, effective January 3, 2022. Following the transition of the Chief Executive Officer role, Mr.
National Drug & Alcohol Research Centre Blog
AUGUST 16, 2021
Professor Shane Darke The term ‘synthetic cannabis’ (or ‘synthetic marijuana’) has been widely used. The term, however, is wrong. This may sound like a pedantic point, but the misnaming of these drugs has potentially dangerous consequences. In a recent article in the International Journal of Drug Policy we proposed that they be referred to as synthetic cannabinoid receptor agonists (SCRAs), to emphasise that this is a drug class entirely distinct from marijuana.
Drug Patent Watch
AUGUST 19, 2021
Annual Drug Patent Expirations for BYDUREON+PEN Bydureon Pen is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-two…. The post New patent for Astrazeneca Ab drug BYDUREON PEN appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
AUGUST 14, 2021
Informa Connect’s Coupon & Copay. Hybrid Event | October 13-20 In-Person: October 13-14 in Philadelphia, PA Virtual: October 19-20 www.informaconnect.com/couponcopay. It’s time to get the gang back together! With an improving landscape, Informa Connect is pleased to announce that Coupon and Copay will return this Fall as a hybrid event, in-person October 13-14 in Philadelphia, PA and virtually October 19-20.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Pharma Data
AUGUST 19, 2021
– Voting is open to the public now through September 1 to help determine this year’s two Thriving Scholars – Forty students living with cystic fibrosis who have demonstrated academic excellence, creativity, and community involvement/extracurricular activities are in the running – Scholarships totaling $25,000 each – the Thriving Undergraduate Scholarship and the Thriving Graduate Scholarship – will be awarded to two deserving students.
The Strateos Blog: Drug Discovery
AUGUST 16, 2021
On July 20th, Strateos hosted a webinar entitled Drug Discovery and Medicinal Chemistry in the Era of Automation. Daniel Rines, Ph.D., Sr. Director of R&D Strategy and Vince Yeh, Ph.D., Director of Chemistry of Strateos gave an interactive talk focused on how automated robotics and integrated software are powering self-driving labs that are revolutionizing synthetic chemistry to support medicinal chemistry workflows.
Drug Patent Watch
AUGUST 19, 2021
Annual Drug Patent Expirations for BYDUREON+BCISE Bydureon Bcise is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are fifteen…. The post New patent for Astrazeneca Ab drug BYDUREON BCISE appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
AUGUST 19, 2021
– In the atogepant Phase 3 ADVANCE trial, participants experienced a significant reduction in migraine and headache days across 12 weeks of treatment¹ – Study also found the majority of atogepant-treated participants achieved at least a 50% reduction in mean monthly migraine days for all doses compared to placebo as a secondary endpoint¹. – Atogepant 30 mg and 60 mg doses demonstrated statistically significant improvements in all six prespecified, multiplicity-controlled second
The Pharma Data
AUGUST 19, 2021
Cancer is the second leading cause of death worldwide, with nearly 10 million deaths annually. 1, 2 In the U.S., approximately 1.9 million new cancer cases are expected to be diagnosed in 2021. 1. Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps determine which solid tumour patients may benefit from GSK immunotherapy. Roche/GSK collaboration represents an important step towards a personalised healthcare strategy for certain solid tumour patients. today announced U.
The Pharma Data
AUGUST 19, 2021
EMA MAA Validation Follows Submission of NDA for Lenacapavir to the U.S. FDA –. – If Authorized, Lenacapavir Would be the First Capsid Inhibitor and the Only HIV-1 Treatment Option Administered Twice Yearly –. today announced that the company’s Marketing Authorization Application (MAA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, has been fully validated and is now under evaluation with the European Medicines Agency (EMA).
The Pharma Data
AUGUST 19, 2021
Sound’s Dual-Technology Platform Uses Biochemistry to Tap into the Natural Capabilities of the Plant to Increase the Speed and Efficiency of Agriculture. Sound Agriculture , a company that is tackling sustainability through groundbreaking advancements in both food and agriculture, announced today that it has secured a USD 45 million investment led by Leaps by Bayer , the impact investment arm of Bayer.
Drug Patent Watch
AUGUST 19, 2021
Annual Drug Patent Expirations for TAFINLAR Tafinlar is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are six patents protecting…. The post New patent for Novartis drug TAFINLAR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 19, 2021
Annual Drug Patent Expirations for MEKINIST Mekinist is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are eight patents protecting…. The post New patent for Novartis drug MEKINIST appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 18, 2021
This chart shows the pharmaceutical companies with the most patents in Norway. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Norway? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 18, 2021
Annual Drug Patent Expirations for EPIDIOLEX Epidiolex is a drug marketed by Gw Res Ltd and is included in one NDA. It is available from one supplier. There are sixteen…. The post New patent for Gw Res drug EPIDIOLEX appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 18, 2021
Annual Drug Patent Expirations for OXLUMO Oxlumo is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are ten patents protecting this drug. This drug…. The post New patent for Alnylam Pharms drug OXLUMO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 18, 2021
Annual Drug Patent Expirations for TRUSELTIQ Truseltiq is a drug marketed by Qed Therap and is included in one NDA. There are three patents protecting this drug. This drug has…. The post New patent for Qed Therap drug TRUSELTIQ appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
AUGUST 17, 2021
To further accelerate COVID-19 research on a global scale, investigators from the University of Colorado Anschutz Medical Campus have created a multidimensional dataset, known as the COVIDome dataset, derived from hospitalized COVID-19 patients versus negative controls. The team has now launched a public online portal called the COVIDome Explorer to share that data in real time.
The Pharma Data
AUGUST 17, 2021
Second FDA approved indication for dostarlimab in 2021 GARNET study demonstrated objective response rate of 41.6% across dMMR solid tumours 95% of responders had a duration of response of ?6 months. GlaxoSmithKline (GSK) plc today announced the US Food and Drug Administration (FDA) approved a new indication for JEMPERLI (dostarlimab-gxly), a programmed cell death receptor-1 (PD-1) blocking antibody, for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced s
Expert insights. Personalized for you.
113 
Let's personalize your content